CEO: Zahed Subhan, Ph.D., MBA, JD, has had over 27 years of extensive experience in guiding pre-clinical and clinical development studies, and gaining regulatory approvals from FDA and EMEA agencies, as well as experience in executing major pharmaceutical product launches with multinational companies. Dr Subhan has also secured more than $25MM seed and venture capital funding for early stage biotechnology companies as Chief Executive Officer. As Chief Business Officer, Dr Subhan also contributed to the $100MM IPO (NASDAQ) of a Life Sciences Company (Gemini Genomics Inc.), and it’s subsequent trade sale to Sequenom Inc. He has a Ph.D. in Pharmacology from the University of Leeds (UK), an MBA from the University of Bradford (UK) and a law degree from the University of London (UK).
President & CSO: Michael O’Rand, Ph.D., is a retired professor in the Department of Cell Biology and Physiology, University of North Carolina at Chapel Hill, School of Medicine. Dr. O’Rand is a reproductive biologist and has more than 35 years of experience in studying mechanisms underlying human fertilization. Dr. O’Rand established the in vitro fertilization laboratory in UNC School of Medicine’s North Carolina Memorial Hospital and the first “test tube” baby in North Carolina. He has 5 issued or pending patents and more than 90 peer-reviewed publications. Dr. O’Rand has an A.B. from the University of California at Berkeley, an M.S. from Oregon State University, Corvallis, Oregon and a Ph.D. in Biology from Temple University, Philadelphia, PA.
COO: Jeffrey A. Handler, Ph.D., DABT, MBA, is a Board certified toxicologist with broad experience in many areas of pharmaceutical and medical device research and development in multiple therapeutic areas, including antibacterials, therapeutic and aesthetic dermatology, stroke, Alzheimer’s disease, diabetes, urinary incontinence and rheumatoid arthritis, obtained over more than 24 years in the pharmaceutical business. He has extensive leadership and management skills within pharmaceutical R&D ranging from drug discovery through development and support of commercialized products and a track record of successful collaboration with colleagues in both scientific and commercial business areas. Dr. Handler has a Ph.D. in Pharmacology (1987) from the University of North Carolina at Chapel Hill and an MBA (2005) from Villanova University, Villanova, PA.
Director of Laboratory Operations: Katherine G. Hamil, is a molecular biologist/biochemist with extensive experience in laboratory management and over 22 years of experience with molecular biology, biochemistry, and tissue culture techniques in the laboratory, with numerous publications in reproductive biology. She has an M.S. and B.S. in biochemistry and cellular and molecular biology from the University of North Carolina at Chapel Hill. NC.